GoAI
Get started
Japan Tissue Engineering Co., Ltd. logo

Japan Tissue Engineering Co., Ltd.

7774.T

JPXHealthcareBiotechnology

Open in GoAI

Latest quote

¥860

−¥2.00 · -0.23%

Aug 24, 3:30 PM JST

7774.T company overview

Regular session · JST · Market data may be delayed.

Company profile

Company website

Japan Tissue Engineering Co., Ltd. operates within the regenerative medicine sector in Japan. The company's activities are organized into three core divisions: Regenerative Medicine Product, Regenerative Medicine Outsourcing, and Research and Development Support. It manufactures and delivers autologous cultured tissues, such as epidermis, cartilage, corneal epithelium, and oral mucosal epithelium, to medical institutions for therapeutic applications. The firm also produces other advanced tissue-engineered medical products. Furthermore, Japan Tissue Engineering is involved in the research and development of three-dimensional human cultured tissue models, which are utilized in the development of external-use cosmetics and drugs, as well as for scientific investigations concerning skin and corneal tissues. Additionally, the company provides comprehensive contract development and manufacturing services for regenerative medicine. Established in 1999, Japan Tissue Engineering Co., Ltd. is based in Gamagori, Japan, and functions as a subsidiary of Teijin Limited.

Industry
Biotechnology
Sector
Healthcare
Headquarters
JP
CEO
Kazuto Yamada
Listed since
Dec 28, 2007
Employees
200

Market position

Day range

Current ¥860

52-week range

Current ¥860

Open
¥870
Previous close
¥862
Volume
120.5K
1.08× average
Average volume
111.43K
Average daily volume
Market cap
34.92B JPY
Beta
1.08
Market reference 1
50-day average
¥679.04
+26.65% above average
200-day average
¥601.75
+42.92% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
22.75B JPY
EV / EBITDA
-58.03×
Earnings yield
-3.04%
Free cash flow yield
-2.32%

Profitability & efficiency

Return on equity
-14.43%
Return on assets
-12.93%
Return on invested capital
-10.73%

Financial health

Current ratio
7.46×
Altman Z-score
28.3
Piotroski F-score
3 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends77%36%-5%-46%Gross margin, FY2021: 58.84%Gross margin, FY2022: 54.87%Gross margin, FY2023: 66.30%Gross margin, FY2024: 59.84%Gross margin, FY2025: 56.17%Operating margin, FY2021: -23.68%Operating margin, FY2022: -35.82%Operating margin, FY2023: 5.75%Operating margin, FY2024: -9.71%Operating margin, FY2025: -25.17%Net margin, FY2021: -23.67%Net margin, FY2022: -35.88%Net margin, FY2023: 5.69%Net margin, FY2024: -10.40%Net margin, FY2025: -33.66%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 58.84%. Gross margin FY2022 54.87%. Gross margin FY2023 66.30%. Gross margin FY2024 59.84%. Gross margin FY2025 56.17%. Operating margin FY2021 -23.68%. Operating margin FY2022 -35.82%. Operating margin FY2023 5.75%. Operating margin FY2024 -9.71%. Operating margin FY2025 -25.17%. Net margin FY2021 -23.67%. Net margin FY2022 -35.88%. Net margin FY2023 5.69%. Net margin FY2024 -10.40%. Net margin FY2025 -33.66%.

Income trends

Revenue

2.18B JPY-11.11%

Operating income

−549.45M JPY-130.55%

Net income

−734.75M JPY-187.79%
Income trends across reported periods2.84B JPY1.54B JPY239.93M JPY−1.06B JPYRevenue, FY2021: 2.1B JPYRevenue, FY2022: 2.03B JPYRevenue, FY2023: 2.51B JPYRevenue, FY2024: 2.46B JPYRevenue, FY2025: 2.18B JPYOperating income, FY2021: −498.18M JPYOperating income, FY2022: −728.12M JPYOperating income, FY2023: 144.51M JPYOperating income, FY2024: −238.32M JPYOperating income, FY2025: −549.45M JPYNet income, FY2021: −497.89M JPYNet income, FY2022: −729.32M JPYNet income, FY2023: 143.17M JPYNet income, FY2024: −255.3M JPYNet income, FY2025: −734.75M JPYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 2.1B JPY. Revenue FY2022 2.03B JPY. Revenue FY2023 2.51B JPY. Revenue FY2024 2.46B JPY. Revenue FY2025 2.18B JPY. Operating income FY2021 −498.18M JPY. Operating income FY2022 −728.12M JPY. Operating income FY2023 144.51M JPY. Operating income FY2024 −238.32M JPY. Operating income FY2025 −549.45M JPY. Net income FY2021 −497.89M JPY. Net income FY2022 −729.32M JPY. Net income FY2023 143.17M JPY. Net income FY2024 −255.3M JPY. Net income FY2025 −734.75M JPY.
Metric (JPY)FY2025FY2024FY2023FY2022FY2021
Revenue2.18B JPY2.46B JPY2.51B JPY2.03B JPY2.1B JPY
Cost of goods sold956.6M JPY986.16M JPY847.41M JPY917.2M JPY865.8M JPY
Gross profit1.23B JPY1.47B JPY1.67B JPY1.12B JPY1.24B JPY
Research and development497.32M JPY506.73M JPY407.01M JPY573.32M JPY561.86M JPY
Selling, general, and administrative1.24B JPY1.14B JPY1.06B JPY1.22B JPY1.12B JPY
Operating expenses1.78B JPY1.71B JPY1.52B JPY1.84B JPY1.74B JPY
Interest income9.78M JPY2.61M JPY782K JPY1.14M JPY2.4M JPY
Depreciation and amortization157.38M JPY113.58M JPY97.81M JPY131.45M JPY124.97M JPY
Operating income−549.45M JPY−238.32M JPY144.51M JPY−728.12M JPY−498.18M JPY
Net income−734.75M JPY−255.3M JPY143.17M JPY−729.32M JPY−497.89M JPY

Company facts updated Aug 24, 2026.

7774.T peers

Chugai Pharmaceutical Co., Ltd. logo

4519.T

Chugai Pharmaceutical Co., Ltd.

¥6,987

-0.34%

Takeda Pharmaceutical Company Limited logo

4502.T

Takeda Pharmaceutical Company Limited

¥5,797

+0.57%

HOYA Corporation logo

7741.T

HOYA Corporation

¥24,895

0.00%

Otsuka Holdings Co., Ltd. logo

4578.T

Otsuka Holdings Co., Ltd.

¥12,210

+0.12%

Daiichi Sankyo Company, Limited logo

4568.T

Daiichi Sankyo Company, Limited

¥2,858

+0.86%

Astellas Pharma Inc. logo

4503.T

Astellas Pharma Inc.

¥2,406.5

+0.82%

Continue in GoAI

Research 7774.T

research.disclaimer